Radiation therapy remains the primary method of treatment for patients with head and neck cancer. The tissue destruction and functional alterations in the oral cavity lead to the development of ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without ...

HPV-related throat cancers are rising, but risks can be lowered by avoiding tobacco, limiting alcohol, getting vaccinated, ...

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

The primary endpoint was the mean normalcy of diet score on the clinician-rated Performance Status Scale for Head and Neck at 1 year. The mean score was 91.6 in the dose-reduction arm and 92.6 in the ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

Dana-Farber Brigham Cancer Center-led phase 3 clinical trial shows that pembrolizumab before and after standard-of-care surgery significantly extends ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

The FDA granted regenerative medicine advanced therapy designation to iltamciocel for patients with oropharyngeal dysphagia ...

“Non-surgical treatments include radiation, chemotherapy, and immunotherapy. But for head and neck cancer, the majority of ...